Dosing & Uses
Breast Cancer
Pending FDA approval in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen
Next:
Pharmacology
Mechanism of Action
AKT (protein kinase B [PKB]) is the collective name of a set of 3 serine/threonine-specific protein kinases
Capivasertib is an adenosine triphosphate (ATP)-competitive inhibitor of all 3 AKT isoforms (AKT1/2/3)
Inhibition of AKT prevents phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
